Phathom Pharmaceuticals (PHAT) Net Equity Issued and Repurchased (2018 - 2023)

Phathom Pharmaceuticals (PHAT) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $38.7 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $38.7 million; the TTM figure through Sep 2024 stood at $38.7 million (changed 0.07% YoY), while the FY2023 annual figure was $14.1 million, down 42.78% from the prior year.
• Net Equity Issued and Repurchased advanced to $38.7 million in Q4 2023 per PHAT's latest filing, from $1000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $88.6 million in Q4 2020 and bottomed at $1000.0 in Q2 2023.
• Historically, Net Equity Issued and Repurchased has averaged $33.2 million across 3 years, with a median of $24.6 million in 2022.